Navigation Links
ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:3/6/2009

disease.

The Company believes that microplasmin may represent a major advance in this area, as detaching the vitreous from the retina has been associated with greatly reducing the growth of new blood vessels (neovascularization) on the retina, which plays a fundamental role in the loss of vision in many diabetic patients.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commented, "We are very pleased to announce the completion of enrolment in MIVI II DME. This initial study is an important first step in evaluating microplasmin's effect in the diabetic retinopathy population in general. Microplasmin could represent an important treatment option for this patient population, given numerous studies from various groups showing the clinical benefits of vitreous detachment in diabetic retinopathy."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product Microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at '/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
2. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
3. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
4. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
5. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
6. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
7. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
8. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
11. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015  Oncobiologics, Inc., a biotherapeutics company focused ... has completed the construction of its GMP commercial ... Cranbury, New Jersey . ... designed to utilize multiple technologies that enable rapid ... the use of the latest single-use technologies, the ...
(Date:5/4/2015)... 4, 2015  Clinical Support Services, Inc. (CSS) ... completed preliminary analysis of Pharmacologic Adverse Events in ... Clinical Support Services, Inc. clinical staff were used ... currently taking psychiatric medications to assess the frequency ... 93% of patients experienced at least one ADE ...
(Date:5/4/2015)... PLEASANTON, Calif. , May 4, 2015 ... its coming out to this year,s PEGS conference and ... protein stability system for biologics. PEGS: The Essential Protein ... , May 4-8, 2015. The UNit lets ... than any other tool out there. Its 7 applications, ...
Breaking Medicine Technology:Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 2Clinical Support Services, Inc. Verifies That Increased Availability of MTM Services Facilitates Identification of Adverse Drug Effects in Psychiatric Patients 3Unchained Labs Lets the UNit Loose 2
(Date:5/4/2015)... May 04, 2015 Milton Hershey School® ... 2015 Alumnus of the Year, recognizing his commitment to ... philanthropy he sets for MHS students. , “Dr. Graves ... happen when children are provided a top-notch education, a ... their passions,” said Pete Gurt ’85, president of MHS. ...
(Date:5/4/2015)... Georgia (PRWEB) May 04, 2015 Each year, ... country to raise funds and awareness for breast cancer. This ... Surgery will be featured as the entertainment sponsor for the ... Cure” on May 9 at the Lenox Square Mall. , ... Atlanta race, and to raise $1.2 million. Perimeter Plastic Surgery ...
(Date:5/4/2015)... May 04, 2015 Getting patients to ... their health is critical to achieving the “triple aim” ... costs, but this will require a shift in thinking ... demands that health systems move beyond their traditional boundaries ... part in the third live meeting of the ...
(Date:5/4/2015)... May 04, 2015 “ LiveSchool ” ... AppWatch, which takes a look at the latest and ... Windows. Joe Toohey, the host of AppWatch and technology ... how this application allows teachers to reward students with ... some realize, especially in the classroom. And the ...
(Date:5/4/2015)... Orange, NJ (PRWEB) May 04, 2015 ... non-profit organization devoted exclusively to funding innovative lymphoma research ... of education programs, outreach initiatives and patient services – ... at the historic Mayfair Farms in West Orange, NJ ... raised nearly $500,000 for innovative research programs through LRF. ...
Breaking Medicine News(10 mins):Health News:Milton Hershey School Names 2015 Alumnus of the Year 2Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2
... SEATTLE, July 31 Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ... results for,second quarter and first six months ended June ... 2008. The company,s earnings conference call will take,place Aug. ... Both live events will be available for viewing ...
... CHAPEL HILL A common vaginal infection may make women ... University of North Carolina at Chapel Hill School of Public ... studies, including data from more than 30,700 women from around ... most common type of vaginosis in women of reproductive age ...
... As tens of thousands of Americans,prepare to attend the ... injury or illness -- and how to deal with ... adequate, appropriate medical care in foreign lands can be,daunting, ... themselves,peace of mind," said Angelo Masciantonio, CEO and co-founder ...
... the Commission will dialogue with leaders at,the Conference to ... HIV/AIDS pandemic, NEW YORK, July 30 Hispanics ... it is estimated that more,than 200,000 individuals had been ... a crisis level. Representing only 15.3% of,the population in ...
... Support, Name, Vision Also Announced, ROCHESTER, Mich., ... approved the appointment of Robert,Folberg, M.D., as the ... open with Beaumont Hospitals in 2010 with a ... announced the official name of the,school -- Oakland ...
... NBC,s Top-Rated Show - The Office - Are Raising Funds for ... ... Research Foundation,(LRF) takes this opportunity to thank the many "employees" of ... the charity,their branch will support during the DMI,s "Summer Splash - ...
Cached Medicine News:Health News:Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call 2Health News:UNC study: Common vaginal infection may increase risk of HIV infection 2Health News:Americans Attending Beijing Olympics Should Plan Ahead for Medical Emergencies 2Health News:The Latino Commission on AIDS Releases Report on the State of HIV/AIDS in Latino/Hispanic Communities in the United States on the Eve of the International AIDS Conference in Mexico City 2Health News:OU, Beaumont Name Dean of New Medical School 2Health News:OU, Beaumont Name Dean of New Medical School 3Health News:Thank You, Dunder Mifflin Infinity 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: